In the brain, release of GSH from astrocytes is an important component of GSH homeostasis

s for Fabry KO mice compared to Fabry KO mice treated with 3 mg/kg intravenous ERT 3 weeks before. There were no significant differences in PQ, QRS, or corrected QT intervals. ERT had no effect 3 weeks after injection on heart weight for Fabry ” KO mice, when normalized to body weight or tibial length. There was no effect 3 weeks after injection on heart weight for WT mice, when normalized to body weight or tibial length. LV GFT-505 cost Molecular Alterations in Fabry KO Mice We examined myocardial alterations that could be associated with cardiac remodeling and dysfunction by analyzing mRNA expression for atrial natriuretic factor brain natriuretic peptide, plasminogen activator inhibitor-1; connective tissue growth factor, thrombospondin 1, and thrombospondin 2. As shown in Left Ventricle and Aortic Structural Alterations with ERT The echocardiography results for 67 month-old Fabry KO mice are summarized in 4 Cardiomyopathy in Fabry Mouse Model age-matched controls according to a trend toward decrease in LV diameter after treatment without change in wall thickness. There was a significant decrease in the aortic diameter during diastole for Fabry KO mice treated with ERT compared to the age-matched KO controls. Left Ventricular Functional Alterations in Fabry KO Mice with ERT The heart rates obtained in 67 week old mice undergoing echocardiography with isoflurane anesthesia were the same for untreated Fabry KO mice compared to age-matched Fabry KO mice that had received ERT as a single IV injection 3 weeks before evaluation. LV systolic function, as assessed by echocardiography was similar in ERT-treated Fabry KO mice as compared to agematched untreated KO mice. Model mice had similar diastolic LV function as the untreated KO controls. LV Molecular Alterations in Fabry KO and WT Mice Treated with ERT As shown in ” mRNA normalized to GAPDH levels in ERT-treated WT mice, but there were not any effects of ERT on any of the mRNA levels examined in this series compared to WT concurrent control male mice. Discussion In the present study, we define the cardiac phenotype in male Fabry KO mice. We found that these mice have bradycardia and low systemic blood pressures compared to the control WT strain, as well as mild hypertrophic cardiomyopathy on echocardiography and gravimetry. The heart rates and systolic blood pressures reported herein for the WT mice are very similar to previous reports. Thus KO Fabry mice displayed a mild hypertrophic cardiomyopathy with structural and functional alteration similar to that described for the early stages of human myocardiopathies. Our results are similar to and extend the findings of Rozenfeld et al., who have described changes in passive pressure volume curves and contractility measurements in the male mouse KO model of Fabry disease, but did not document hypertrophy as assessed by cardiac weight normalized to tibial length or echo cardiographic assessment of left ventricular mass. The initial descriptions of the KO model of Fabry disease were used for pharmacokinetic studies of ERT, and did not evaluate the phenotype of these animals. Shayman et al. have studied large vessel reactivity and pathology in this model but did not evaluated the cardiac findings. The most striking aspect of the cardiac phenotype in the KO mice was hypotension and bradycardia, compared to the WT controls. Autonomic nervous system alteration, as assessed on heart rate variability, was described in children and adolescents with decreased heart ra